DaVita Inc. (NYSE:DVA) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its holdings in shares of DaVita Inc. (NYSE:DVA) by 12.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,696 shares of the company’s stock after selling 844 shares during the quarter. Mutual of America Capital Management LLC’s holdings in DaVita were worth $934,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in DVA. Transcendent Capital Group LLC purchased a new stake in DaVita during the third quarter worth approximately $25,000. Blue Trust Inc. boosted its holdings in shares of DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after buying an additional 78 shares in the last quarter. Family Firm Inc. purchased a new position in shares of DaVita in the 2nd quarter valued at $43,000. Versant Capital Management Inc raised its stake in DaVita by 90.6% during the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after acquiring an additional 155 shares in the last quarter. Finally, Friedenthal Financial purchased a new stake in DaVita in the second quarter valued at $48,000. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Trading Up 0.6 %

NYSE:DVA opened at $167.98 on Wednesday. DaVita Inc. has a 12-month low of $98.26 and a 12-month high of $169.12. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The stock’s 50 day simple moving average is $158.34 and its 200-day simple moving average is $148.65. The firm has a market cap of $13.77 billion, a P/E ratio of 18.12, a PEG ratio of 0.93 and a beta of 0.89.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same period in the prior year, the firm posted $2.85 earnings per share. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. Equities analysts anticipate that DaVita Inc. will post 9.71 EPS for the current year.

Insider Activity at DaVita

In other news, CEO Javier Rodriguez sold 9,881 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the completion of the transaction, the chief executive officer now directly owns 887,835 shares of the company’s stock, valued at approximately $144,583,929.75. This represents a 1.10 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.00% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on DVA shares. Barclays lifted their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Truist Financial boosted their price objective on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. UBS Group increased their price objective on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Bank of America lifted their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.